A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer.A southeastern cancer study group project
- 1 August 1977
- Vol. 40 (2) , 625-632
- https://doi.org/10.1002/1097-0142(197708)40:2<625::aid-cncr2820400206>3.0.co;2-m
Abstract
In an ongoing prospective randomized study, 113 evaluable patients have received either a three-drug combination that included cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) or a five-drug combination including cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) given intermittently 1 week out of 4. Responses (64%), median duration of response (32 weeks), and median duration of disease control (32 weeks) achieved with CAF were superior to those achieved with CMFVP (37%, 22 weeks, 17 weeks, respectively). Morbidity secondary to CAF was significant, with nausea and vomiting, malaise, total alopecia, and granulocytopenia being the main features. Cancer 40:625–632, 1977.This publication has 2 references indexed in Scilit:
- Combination chemotherapy of carcinoma of the breastCancer Treatment Reviews, 1974
- A generalized Wilcoxon test for comparing arbitrarily singly-censored samplesBiometrika, 1965